使用低剂量正电子发射数字乳腺摄影系统检测乳腺癌
这项前瞻性研究纳入25例新诊断乳腺癌女性,评估低剂量正电子发射乳腺摄影(PEM)与MRI同步检查识别乳腺癌及局部范围的可行性。25例中24例(96%)癌症被PEM识别,包括19例浸润性癌和5例原位病变;PEM漏诊3例原位2级病变。PEM检测到的假阳性额外病变少于MRI(1/6 vs 8/13,P=0.14),但差异未达统计学显著。
要点
- 低剂量PEM在注射18F-FDG后1小时和4小时图像上识别了25例中24例(96%)乳腺癌,包括19例浸润性癌和5例原位病变。
- PEM漏诊3例原位2级病变,浸润性癌中位大小31 mm(范围10-120 mm)。
- PEM检测到的假阳性额外病变少于MRI(1/6 vs 8/13,P=0.14),但差异未达统计学显著。
核心结论
- 本研究提示低剂量PEM系统在帮助检测浸润性乳腺癌方面具有可行性;作者指出需要大规模临床试验来确认这些初步结果,并强调该低剂量PEM系统作为乳腺癌诊断中有前景的成像工具的潜力。
研究设计与样本
- 研究伦理委员会批准的前瞻性研究,纳入25例新诊断乳腺癌女性(中位年龄52岁,范围32-85岁),不限乳腺密度、肿瘤大小和组织病理学亚型,均行低剂量PEM(最多185 MBq 18F-FDG)并同步行乳腺MRI;两名不知晓癌症位置的乳腺放射科医生阅片,评估注射后1小时和4小时PEM图像,并与组织病理学结果对照。
诊断标准与关键数值
- PEM从100组双侧图像中识别25例中24例(96%)癌症,包括19例浸润性癌和5例原位病变;注射放射性示踪剂3小时后仍显示可比性能;PEM漏诊3例原位2级病变;PEM检测到的假阳性额外病变为6例中1例(16%),MRI为13例中8例(62%),P=0.14。
局限性
- 作者指出需要大规模临床试验来确认这些初步结果;PEM检测到的假阳性额外病变少于MRI,但差异未达统计学显著(P=0.14);PEM漏诊3例原位2级病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate the feasibility of low-dose positron emission mammography (PEM) concurrently to MRI to identify breast cancer and determine its local extent. Materials and Methods In this research ethics board-approved prospective study, participants newly diagnosed with breast cancer with concurrent breast MRI acquisitions were assigned independently of breast density, tumor size, and histopathologic cancer subtype to undergo low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose (18F-FDG). Two breast radiologists, unaware of the cancer location, reviewed PEM images taken 1 and 4 hours following 18F-FDG injection. Findings were correlated with histopathologic results. Detection accuracy and participant details were examined using logistic regression and summary statistics, and a comparative analysis assessed the efficacy of PEM and MRI additional lesions detection (ClinicalTrials.gov: NCT03520218). Results Twenty-five female participants (median age, 52 years; range, 32-85 years) comprised the cohort. Twenty-four of 25 (96%) cancers (19 invasive cancers and five in situ diseases) were identified with PEM from 100 sets of bilateral images, showcasing comparable performance even after 3 hours of radiotracer uptake. The median invasive cancer size was 31 mm (range, 10-120). Three additional in situ grade 2 lesions were missed at PEM. While not significant, PEM detected fewer false-positive additional lesions compared with MRI (one of six [16%] vs eight of 13 [62%]; P = .14). Conclusion This study suggests the feasibility of a low-dose PEM system in helping to detect invasive breast cancer. Though large-scale clinical trials are essential to confirm these preliminary results, this study underscores the potential of this low-dose PEM system as a promising imaging tool in breast cancer diagnosis. ClinicalTrials.gov registration no. NCT03520218 Keywords: Positron Emission Digital Mammography, Invasive Breast Cancer, Oncology, MRI Supplemental material is available for this article. © RSNA, 2024 See also commentary by Barreto and Rapelyea in this issue.
引用
- Freitas V, Li X, Scaranelo A, et al. Breast Cancer Detection Using a Low-Dose Positron Emission Digital Mammography System. Radiol Imaging Cancer. 2024. PMID: 38334470. doi:10.1148/rycan.230020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。